A randomized controlled study on color stability of tetracycline teeth restored with ceramic veneer.

OBJECTIVES: This study aimed to evaluate the color stability of tetracycline teeth restored with ceramic veneers of different thicknesses combined with different resin cement systems after aging. METHODS: Twenty patients with tetracycline teeth, including two maxillary central incisors, were selected clinically. The patients were randomly divided into four groups and restored with 0.5 and 0.75 mm ceramic veneers by using a veneer adhesive system, either with light-cured or dual-cured reaction. The color difference (ΔE) values after cementation and 1, 6, 12, and 24 months of use were obtained by quantification of L*, a*, and b* values with a colorimeter. The results were analyzed statistically with two-way ANOVA and Student's t test. RESULTS: The ΔE values of ceramic veneers detected after aging were less than 2.25. The 0.5 mm groups exhibited greater color change than the 0.75 mm-thick veneers (P<0.05). No significant difference was found on the color change of dual- or light-cured resin cements. CONCLUSIONS: Resin cements and veneer thickness influence the color of ceramic veneers after aging. Cementation of veneers with either dual- or light-cured resin cements does not affect the long-term color stability of tetracycline teeth differently.

Antimicrobial effects of a bioactive glass combined with fluoride or triclosan on Streptococcus mutans biofilm.

OBJECTIVE: The objective of this study was to investigate the antibacterial effects on a cariogenic biofilm of a bioactive glass (BAG) combined with either sodium fluoride (NaF) or triclosan (TCS). DESIGN: According to minimal bactericidal concentrations, 37.5mg/ml of BAG, 4.69 mg/ml of NaF, and 15.53 µg/ml of TCS solutions were prepared. When used alone, the three antimicrobial solutions were increased to double-dosage strength (2 MBC). The study contained the following experimental groups: group 1, BAG (2 MBC); group 2, NaF (2 MBC); group 3, TCS (2 MBC); group 4, BAG+NaF; group 5, BAG+TCS; group 6, control (saline). Streptococcus mutans biofilm was cultured with 0.1% sucrose anaerobically on 66 sterilized coverslips (1 × 1 cm(2)) for 24h uninterrupted. After 10 min of exposure to the experimental groups, the microbial kinetics, morphology, and viability of the S. mutans biofilms were assessed by evaluation of colony-forming units (CFUs), scanning electron microscopy (SEM), and confocal laser scanning microscopy (CLSM). RESULTS: BAG (2 MBC) used alone showed significantly stronger antibacterial effects than the other two antimicrobials used alone. The combination groups also displayed the same or greater biofilm inactivation effects as BAG (2 MBC) in the plate count test. SEM showed smaller stacks (towers) and fewer surrounding bacteria in groups BAG (2 MBC), BAG+NaF, and BAG+TCS. Confocal microscopy also determined higher live/dead ratios in groups NaF (2 MBC), TCS (2 MBC), and control than in groups BAG (2 MBC), BAG+NaF, and BAG+TCS. CONCLUSIONS: The combinations of BAG with either NaF or TCS enhanced the inactivation effects of BAG (2 MBC) on S. mutans biofilm, and these findings should be further investigated clinically for the control of dental biofilms.

Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.

PURPOSE: ORM1 is a plasma drug binding protein. Its polymorphism rs17650 (S>F) has been reported to be an important factor affecting the binding ability and effect of antiretroviral protease inhibitors. The aim of this study was to determine whether the ORM1 rs17650 polymorphism also influences warfarin therapy. METHODS: A total of 191 Chinese patients with steady-dose warfarin therapy were enrolled in this study. The patients were studied for warfarin maintenance dose, the ORM1 rs17650 polymorphism, and two polymorphisms previously demonstrated to affect warfarin response [CYP2C9 rs1057910 (3) and VKORC1 rs7294 (-1639 G>A)]. RESULTS: Warfarin dose was partially correlated with the VKORC1 rs7294, CYP2C9 rs1057910 and ORM1 rs17650 polymorphisms. Patients carrying the wild-type of these three genes (n = 96) took a mean dose of 3.0 ± 1.1 mg warfarin, which was significantly higher than that taken by the 52 S patients (2.7 ± 0.7) and 11 S S patients (2.5 ± 0.6 mg) (p = 0.048). CONCLUSION: We identified ORM1 as another polymorphic gene affecting warfarin dose requirements. ORM1 S carriers require lower maintenance doses to achieve and maintain an optimal level of anticoagulation.